Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
|Articles|October 2, 2015
- BioPharm International-10-15-2015
- Volume 2015 eBook
- Issue 2
Aseptic Processing for Cytotherapy, Regenerative Medicine, and Tissue-Engineered Products
Author(s)Mamoru Kokubo, James E. Akers
Isolators offer a safety and economic advantage for next-generation regenerative medicine products.
Advertisement
BioPharm International
eBooks Volume 28, Issue 14
Manufacturing advanced biologics demands solutions that are quite different from what is being used for large-scale industrial biologics processing today. This article touches on approaches that work with advanced biologics. Read this article and other articles in
BioPharm International
's 2015
eBook.
Articles in this issue
almost 11 years ago
Fluctuating Capacity and Demand Conditions in Biomanufacturingalmost 11 years ago
Cleaning Validation for Biologicsalmost 11 years ago
Automation of Single-Use Systemsalmost 11 years ago
Are Biopharma Patents Poised on the Post-Grant Chopping Block?almost 11 years ago
Raising the Bar for Biopharma TrainingAdvertisement
Related to this article
Vironexis Biotherapeutics reported that the first three antibody-naive patients with relapsed/refractory acute lymphoblastic leukemia treated with its one-time in vivo immunotherapy VNX-101 all achieved MRD-negative complete responses, with durability tracked through at least nine months.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Advertisement
Advertisement